Please wait while the formulary information is being retrieved.
REMODULIN (TREPROSTINIL SODIUM)
- Pulmonary arterial hypertension
1 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
10 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
2.5 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
5 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
sodium 1 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
sodium 10 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
sodium 2.5 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
sodium 5 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
1 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
10 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
2.5 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
5 mg/mL injection solution
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
Pulmonary arterial hypertension
- Infuse 1.25 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
- Infuse 2.5 nanogram/kg/minute via subcutaneous infusion pump by cont subcutan infusi route
- Infuse 3.75 nanogram/kg/minute via subcutaneous infusion pump by contsubcutan infusi route
- Infuse 5 nanogram/kg/minute via subcutaneous infusion pump by cont subcutan infusi route
- Infuse 7.5 nanogram/kg/minute via subcutaneous infusion pump by cont subcutan infusi route
- Infuse 1.25 nanogram/kg/minute via infusion pump by continuous infusion route
- Infuse 2.5 nanogram/kg/minute via infusion pump by continuous infusion route
- Infuse 3.75 nanogram/kg/minute via infusion pump by continuous infusion route
- Infuse 5 nanogram/kg/minute via infusion pump by continuous infusion route
- Infuse 7.5 nanogram/kg/minute via infusion pump by continuous infusion route
- Infuse 0.625 nanogram/kg/minute via infusion pump by continuous infusion route
- Infuse 0.625 nanogram/kg/minute via subcutaneous infusion pump by cont subcutan infusi route
- None
Contraindicated
- None
Severe
Moderate
- gemfibrozil
- Lopid
- None
Contraindicated
- Disease of liver
- Kidney disease with reduction in GFR
Severe
Moderate
- Hypotension
- Increased risk of bleeding
REMODULIN (TREPROSTINIL SODIUM)
- Pulmonary arterial hypertension
- Edema
- Erythema
- Hypotension
- Injection site sequelae
- Acute abdominal pain
- Diarrhea
- Dizziness
- Headache disorder
- Jaw pain
- Nausea
- Pruritus of skin
- Skin rash
More Frequent
Severe
Less Severe
- None
- Anorexia
- General weakness
- Vasodilation of blood vessels
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Thrombocytopenic disorder
- Thrombophlebitis
Less Severe
- Arthralgias
- Bone pain
- Cellulitis
- Limb pain
- Maculopapular rash
- Muscle spasm
- Myalgias
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Treprostinil (Oral,Inj)
No safety and efficacy established.
- 1 Day – 16 Years
- No safety and efficacy established.
Treprostinil (inh, Inj)
- Severity Level:
2
- Additional Notes: Insufficient human data, animal data suggest low risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Treprostinil
Insufficient data available; may be excreted given low molecular wt
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; may be excreted given low molecular wt |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Treprostinil
General-Start at lower doses especially if renal or hepatic insufficiency. Monitor carefully and titrate dosage. Cardiovascular-May cause hypotension, especially with low underlying arterial pressure.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Pulmonary arterial hypertension | |
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
| 0-9 | A-Z |
|---|---|
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
Formulary Reference Tool